I don't think it's funny unless you find giving the legal department more work to be funny. Seriously, I think Teva knows this CP will be rejected. The purpose seems to be discussing the five criteria from generic Lovenox approval with regard to Copaxone and also asking for an advisory committee.
Market Data 
Markets 
AI
